- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 3.14 Å
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 2 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN.2: 8 residues within 4Å:- Chain A: N.256, T.258, N.259
- Chain C: Q.1, H.3, Y.25, G.26, N.28
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:Y.25, C:Q.1, C:Q.1
NAG-NAG-BMA-MAN-MAN-MAN.10: 9 residues within 4Å:- Chain E: N.256, T.258, N.259
- Chain G: Q.1, H.3, Y.25, G.26, V.27, N.28
2 PLIP interactions:2 interactions with chain G- Hydrogen bonds: G:Q.1, G:Q.1
NAG-NAG-BMA-MAN-MAN-MAN.19: 8 residues within 4Å:- Chain I: N.256, T.258, N.259
- Chain K: Q.1, H.3, Y.25, G.26, N.28
2 PLIP interactions:2 interactions with chain K- Hydrogen bonds: K:Y.25, K:Q.1, K:Q.1
- 3 x NAG- NAG- NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-NAG-NAG.3: 11 residues within 4Å:- Chain A: T.277, Y.309, N.311, T.387
- Chain M: Q.102, R.103, I.104, G.106, V.107
- Chain N: D.62, I.63
4 PLIP interactions:3 interactions with chain M, 1 interactions with chain N- Hydrophobic interactions: M:I.104
- Hydrogen bonds: M:R.103, M:I.104, N:D.62
NAG-NAG-NAG-NAG.12: 11 residues within 4Å:- Chain E: T.277, Y.309, N.311
- Chain O: R.103, I.104, G.106, V.107, V.108
- Chain P: Q.47, D.62, I.63
2 PLIP interactions:1 interactions with chain P, 1 interactions with chain O- Hydrogen bonds: P:Q.47, O:R.103
NAG-NAG-NAG-NAG.22: 11 residues within 4Å:- Chain I: T.277, Y.309, N.311, T.387
- Chain Q: R.103, I.104, Y.105, G.106, V.107, V.108
- Chain R: D.62
2 PLIP interactions:1 interactions with chain Q, 1 interactions with chain R- Hydrogen bonds: Q:R.103, R:D.62
- 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.4: 3 residues within 4Å:- Chain A: M.351, N.364, T.366
No protein-ligand interaction detected (PLIP)NAG-NAG.5: 1 residues within 4Å:- Chain A: N.370
No protein-ligand interaction detected (PLIP)NAG-NAG.6: 3 residues within 4Å:- Chain A: V.155, R.172, N.177
1 PLIP interactions:1 interactions with chain A- Hydrophobic interactions: A:V.155
NAG-NAG.11: 4 residues within 4Å:- Chain E: N.129, Y.146, L.148, D.300
No protein-ligand interaction detected (PLIP)NAG-NAG.13: 4 residues within 4Å:- Chain E: M.351, N.364, T.366
- Ligands: NAG-NAG.14
No protein-ligand interaction detected (PLIP)NAG-NAG.14: 2 residues within 4Å:- Chain E: N.370
- Ligands: NAG-NAG.13
No protein-ligand interaction detected (PLIP)NAG-NAG.15: 2 residues within 4Å:- Chain E: R.172, N.177
No protein-ligand interaction detected (PLIP)NAG-NAG.20: 4 residues within 4Å:- Chain I: N.129, Y.146, L.148, D.300
1 PLIP interactions:1 interactions with chain I- Hydrogen bonds: I:D.300
NAG-NAG.21: 5 residues within 4Å:- Chain I: E.248, G.249, I.250, N.269, R.323
1 PLIP interactions:1 interactions with chain I- Hydrogen bonds: I:R.323
NAG-NAG.23: 5 residues within 4Å:- Chain I: T.350, M.351, N.364, T.366
- Ligands: NAG.60
No protein-ligand interaction detected (PLIP)NAG-NAG.24: 4 residues within 4Å:- Chain I: V.155, R.172, N.177, T.178
1 PLIP interactions:1 interactions with chain I- Hydrophobic interactions: I:V.155
NAG-NAG.25: 2 residues within 4Å:- Chain I: N.101, F.168
No protein-ligand interaction detected (PLIP)- 5 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.7: 8 residues within 4Å:- Chain A: D.191, N.242, N.355, R.357, C.417, L.418, S.419
- Ligands: NAG.33
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:L.418
NAG-NAG-BMA.8: 9 residues within 4Å:- Chain B: N.126
- Chain D: N.32, Y.50, R.51, A.53, A.54, L.55, L.56, A.67
1 PLIP interactions:1 interactions with chain D- Hydrogen bonds: D:Y.50
NAG-NAG-BMA.16: 7 residues within 4Å:- Chain E: D.191, N.242, N.355, C.356, C.417, L.418, S.419
1 PLIP interactions:1 interactions with chain E- Hydrogen bonds: E:L.418
NAG-NAG-BMA.17: 9 residues within 4Å:- Chain F: N.126
- Chain H: N.32, Y.50, R.51, A.53, A.54, L.55, L.56, A.67
2 PLIP interactions:2 interactions with chain H- Hydrogen bonds: H:Y.50, H:L.55
NAG-NAG-BMA.26: 7 residues within 4Å:- Chain I: D.191, N.242, N.355, R.357, C.417, L.418, S.419
3 PLIP interactions:3 interactions with chain I- Hydrogen bonds: I:R.357, I:D.191, I:C.356, I:L.418
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x 83J: 1-[4-(benzenecarbonyl)piperazin-1-yl]-2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]ethane-1,2-dione(Non-covalent)
83J.28: 16 residues within 4Å:- Chain A: I.80, W.83, D.84, L.87, K.182, V.235, S.353, F.360, Y.362, I.396, N.397, M.398, W.399, Q.404, A.405, M.406
8 PLIP interactions:8 interactions with chain A- Hydrophobic interactions: A:K.182, A:V.235, A:F.360, A:I.396, A:W.399, A:Q.404
- Hydrogen bonds: A:D.84, A:W.399
83J.46: 16 residues within 4Å:- Chain E: I.80, W.83, D.84, L.87, K.182, V.235, S.353, F.354, Y.362, I.396, N.397, M.398, W.399, Q.404, A.405, M.406
7 PLIP interactions:7 interactions with chain E- Hydrophobic interactions: E:K.182, E:V.235, E:Q.404
- Hydrogen bonds: E:D.84, E:D.84, E:W.399
- pi-Stacking: E:F.360
83J.59: 18 residues within 4Å:- Chain I: I.80, W.83, D.84, L.87, K.182, V.235, S.353, F.354, F.360, Y.362, I.396, N.397, M.398, W.399, Q.404, A.405, M.406, M.448
9 PLIP interactions:9 interactions with chain I- Hydrophobic interactions: I:K.182, I:V.235, I:F.360, I:Y.362, I:I.396, I:W.399
- Hydrogen bonds: I:D.84, I:D.84, I:W.399
- 34 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.29: 2 residues within 4Å:- Chain A: N.133
- Ligands: NAG.36
Ligand excluded by PLIPNAG.30: 2 residues within 4Å:- Chain A: H.56, N.221
Ligand excluded by PLIPNAG.31: 5 residues within 4Å:- Chain A: N.275, I.312, S.313, T.385, L.418
Ligand excluded by PLIPNAG.32: 5 residues within 4Å:- Chain A: N.281, N.282, T.283, I.302, K.412
Ligand excluded by PLIPNAG.33: 4 residues within 4Å:- Chain A: N.242, S.271, N.420
- Ligands: NAG-NAG-BMA.7
Ligand excluded by PLIPNAG.34: 4 residues within 4Å:- Chain A: N.129, Y.146, L.148, D.300
Ligand excluded by PLIPNAG.35: 2 residues within 4Å:- Chain A: N.269, R.323
Ligand excluded by PLIPNAG.36: 3 residues within 4Å:- Chain A: N.101, F.168
- Ligands: NAG.29
Ligand excluded by PLIPNAG.37: 2 residues within 4Å:- Chain B: N.105
- Chain D: Q.27
Ligand excluded by PLIPNAG.38: 2 residues within 4Å:- Chain B: N.113, N.114
Ligand excluded by PLIPNAG.39: 3 residues within 4Å:- Chain C: G.65, K.87, N.88
Ligand excluded by PLIPNAG.40: 1 residues within 4Å:- Chain E: N.133
Ligand excluded by PLIPNAG.41: 3 residues within 4Å:- Chain E: H.56, N.209, N.221
Ligand excluded by PLIPNAG.42: 5 residues within 4Å:- Chain E: K.273, N.275, N.311, T.385, L.418
Ligand excluded by PLIPNAG.43: 2 residues within 4Å:- Chain E: N.281, I.302
Ligand excluded by PLIPNAG.44: 4 residues within 4Å:- Chain E: N.326, K.329, E.330, N.334
Ligand excluded by PLIPNAG.45: 2 residues within 4Å:- Chain E: S.271, N.420
Ligand excluded by PLIPNAG.47: 3 residues within 4Å:- Chain E: E.248, G.249, N.269
Ligand excluded by PLIPNAG.48: 3 residues within 4Å:- Chain E: N.101, K.144, F.168
Ligand excluded by PLIPNAG.49: 2 residues within 4Å:- Chain F: N.100, S.102
Ligand excluded by PLIPNAG.50: 1 residues within 4Å:- Chain F: N.105
Ligand excluded by PLIPNAG.51: 1 residues within 4Å:- Chain F: N.114
Ligand excluded by PLIPNAG.52: 2 residues within 4Å:- Chain G: K.87, N.88
Ligand excluded by PLIPNAG.53: 1 residues within 4Å:- Chain I: N.133
Ligand excluded by PLIPNAG.54: 2 residues within 4Å:- Chain I: H.56, N.221
Ligand excluded by PLIPNAG.55: 5 residues within 4Å:- Chain I: N.275, N.311, S.313, T.385, L.418
Ligand excluded by PLIPNAG.56: 3 residues within 4Å:- Chain I: N.281, I.302, V.414
Ligand excluded by PLIPNAG.57: 2 residues within 4Å:- Chain I: K.329, N.334
Ligand excluded by PLIPNAG.58: 3 residues within 4Å:- Chain I: N.242, S.271, N.420
Ligand excluded by PLIPNAG.60: 2 residues within 4Å:- Chain I: N.370
- Ligands: NAG-NAG.23
Ligand excluded by PLIPNAG.61: 3 residues within 4Å:- Chain J: P.98, N.100, I.134
Ligand excluded by PLIPNAG.62: 2 residues within 4Å:- Chain J: N.105
- Chain L: Q.27
Ligand excluded by PLIPNAG.63: 2 residues within 4Å:- Chain J: N.113, N.114
Ligand excluded by PLIPNAG.64: 2 residues within 4Å:- Chain K: G.65, N.88
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Prevost, J. et al., Structure-function analyses reveal key molecular determinants of HIV-1 CRF01_AE resistance to the entry inhibitor temsavir. Nat Commun (2023)
- Release Date
- 2023-05-31
- Peptides
- CRF01_AE T/F100 HIV-1 gp120: AEI
CRF-1_AE T/F100 HIV-1 gp41: BFJ
Heavy chain of 8ANC195 Fab: CGK
Light chain of 8ANC195 Fab: DHL
Heavy chain of 10-1074 Fab: MOQ
Light chain of 10-1074 Fab: NPR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
EI
IB
BF
FJ
JC
CG
GK
KD
DH
HL
LM
MO
OQ
QN
NP
PR
R
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 3.14 Å
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 2 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 12 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 5 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 1 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x 83J: 1-[4-(benzenecarbonyl)piperazin-1-yl]-2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]ethane-1,2-dione(Non-covalent)
- 34 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Prevost, J. et al., Structure-function analyses reveal key molecular determinants of HIV-1 CRF01_AE resistance to the entry inhibitor temsavir. Nat Commun (2023)
- Release Date
- 2023-05-31
- Peptides
- CRF01_AE T/F100 HIV-1 gp120: AEI
CRF-1_AE T/F100 HIV-1 gp41: BFJ
Heavy chain of 8ANC195 Fab: CGK
Light chain of 8ANC195 Fab: DHL
Heavy chain of 10-1074 Fab: MOQ
Light chain of 10-1074 Fab: NPR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
EI
IB
BF
FJ
JC
CG
GK
KD
DH
HL
LM
MO
OQ
QN
NP
PR
R